Emergent BioSolutions Canada Inc., a biopharmaceutical company, develops, manufactures, and commercializes immune therapeutics in North America and internationally. The company operates in two segments, Biopharmaceutical Operations and Contract Services. It develops plasma-derived products, including hyperimmunes, which are concentrated specialty antibody preparations made from specialty plasma; and recombinant biopharmaceuticals that are therapeutic proteins made by introducing a particular gene into a host organism. The company’s product portfolio consists of purified, concentrated antibody preparations (hyperimmunes) with target applications in infectious disease, hematology, transplantation, and biodefense. Its products include WinRho SDF, a purified human immunoglobulin used to treat immune thrombocytopenic purpura; HepaGam B, an antibody that is specific for hepatitis B surface antigen; VariZIG, an antibody specific for Varicella zoster virus; and Vaccinia Immune Globulin Intravenous for Vaccinia virus. The company also provides Botulism Antitoxin Heptavalent containing antibodies specific for the A, B, C, D, E, F, and G botulinum toxin types; Anthrax Immune Globulin, which contains antibodies specific for Bacillus anthracis, the bacterium that cause anthrax; and episil for the management and relief of pain. In addition, it offers contract research and development, and manufacturing services to other biopharmaceutical companies and government organizations. Emergent BioSolutions Canada Inc. was founded in 1984 and is headquartered in Winnipeg, Canada. Emergent BioSolutions Canada Inc. operates as a subsidiary of Emergent BioSolutions, Inc.